Navigation path

Pharmaceuticals - Community Register


Community list of not active orphan medicinal products


Product information


EU orphan designation number: EU/3/09/679
Active ingredient: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Indication: Treatment of progressive supranuclear palsy
Sponsor: NOSCIRA, S.A.
Avda. De la Industria 52, 28760 Tres Cantos (Madrid), España

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
30/10/2009 Orphan designation EMEA/OD/074/09 (2009)8524 of 28/10/2009
21/11/2012 Removal of orphan designation from Community Register